Skip to main content

Akero Therapeutics, Inc.

AKRODelisted Dec 9, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001744659

Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Akero Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Akero Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Akero Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Harrison Seth LoringDirector0Dec 9, 20251
Iwicki Mark TDirector0Dec 9, 20251
Henderson JaneDirector0Dec 9, 20251
Gangloff Scott A.Chief Technology Officer0Dec 9, 20251
Graham G. WalmsleyDirector0Dec 9, 20252
Cheng AndrewPresident and CEO0Dec 9, 20255
White William RichardChief Financial Officer0Dec 9, 20251
Yale CatrionaChief Development Officer0Dec 9, 20252
Rolph TimothyChief Scientific Officer0Dec 9, 20254
Young JonathanChief Operating Officer0Dec 9, 20253
Heyman Tomas J.Director0Dec 9, 20251
Xu YuanDirector0Dec 9, 20251
Judy ChouDirector0Dec 9, 20251
Lamy PatrickSee Remarks0Dec 9, 20251
Ezbon International LtdOther: Former 10% owner3,271,829IndirectDec 5, 20220
Blue Horizon Enterprise LtdOther: Former 10% owner3,271,829IndirectDec 5, 20220
Montrago Trustees LtdOther: Former 10% owner3,271,829IndirectDec 5, 20220
Skorpios TrustOther: Former 10% owner3,271,829IndirectDec 5, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 2, 2024 (view filing)Jul 11 dayYoung JonathanChief Operating OfficerSSale−5.00K$23.40−$117.0K−2.0%246.9K after10b5-1
Jun 13, 2024 (view filing)Jun 112 daysYoung JonathanChief Operating OfficerSSale−2.52K$22.64−$57.0K−1.0%250.8K after
Jun 13, 2024 (view filing)Jun 112 daysYale CatrionaChief Development OfficerSSale−2.83K$22.64−$64.0K−3.6%74.9K after
Jun 13, 2024 (view filing)Jun 112 daysWhite William RichardChief Financial OfficerSSale−2.83K$22.64−$64.1K−5.7%46.8K after
Jun 13, 2024 (view filing)Jun 112 daysRolph TimothyChief Scientific OfficerSSale−2.38K$22.64−$53.9K−1.3%180.2K after
Jun 13, 2024 (view filing)Jun 112 daysLamy PatrickSenior VP, Commercial StrategySSale−569$22.64−$12.9K−3.0%18.6K after
Jun 13, 2024 (view filing)Jun 112 daysCheng AndrewPresident and CEOSSale−7.89K$22.64−$178.7K−1.3%581.6K after
Jun 5, 2024 (view filing)Jun 32 daysYoung JonathanChief Operating OfficerSSale−5.00K$19.29−$96.5K−1.9%253.3K after10b5-1
May 2, 2024 (view filing)May 11 dayYoung JonathanChief Operating OfficerSSale−5.00K$20.15−$100.8K−1.9%258.3K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysYoung JonathanChief Operating OfficerSSale−4.60K$24.33−$111.9K−1.7%263.7K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysYoung JonathanChief Operating OfficerSSaleCommon Stoek−400$25.03−$10.0K−0.2%263.3K after10b5-1
Mar 15, 2024 (view filing)Mar 132 daysYale CatrionaChief Development OfficerSSale−723$28.33−$20.5K−0.9%77.7K after
Mar 15, 2024 (view filing)Mar 132 daysWhite William RichardChief Financial OfficerSSale−724$28.33−$20.5K−1.4%49.6K after
Mar 15, 2024 (view filing)Mar 132 daysCheng AndrewPresident and CEOSSale−1.97K$28.33−$55.8K−0.3%589.4K after
Mar 15, 2024 (view filing)Mar 132 daysYoung JonathanChief Operating OfficerSSale−651$28.33−$18.4K−0.2%268.3K after
Mar 15, 2024 (view filing)Mar 132 daysRolph TimothyChief Scientific OfficerSSale−619$28.33−$17.5K−0.3%182.6K after
Mar 6, 2024 (view filing)Mar 42 daysCheng AndrewPresident and CEOSSale−75.0K$32.87−$2.46M−11.3%591.4K after6 lots10b5-1
Mar 6, 2024 (view filing)Mar 42 daysYale CatrionaChief Development OfficerSSale−20.6K$35.49−$732.7K−20.8%78.4K after10b5-1
Dec 29, 2023 (view filing)Dec 272 daysYoung JonathanChief Operating OfficerSSale−5.41K$24.00−$129.9K−2.8%185.1K after
Dec 18, 2023 (view filing)Dec 144 daysYale CatrionaChief Development OfficerSSale−597$20.76−$12.4K−0.8%77.9K after
Dec 18, 2023 (view filing)Dec 144 daysWhite William RichardChief Financial OfficerSSale−611$20.76−$12.7K−1.2%50.4K after
Dec 18, 2023 (view filing)Dec 144 daysYoung JonathanChief Operating OfficerSSale−543$20.76−$11.3K−0.3%185.1K after
Dec 18, 2023 (view filing)Dec 144 daysCheng AndrewPresident and CEOSSale−1.63K$20.76−$33.8K−0.3%550.9K after
Dec 18, 2023 (view filing)Dec 144 daysRolph TimothyChief Scientific OfficerSSale−514$20.76−$10.7K−0.3%182.7K after
Dec 11, 2023 (view filing)Dec 83 daysGraham G. WalmsleyDirectorPPurchase+100.0K$19.83+$1.98M+14.3%800.0K after2 lots
Dec 11, 2023 (view filing)Dec 7-114 daysCheng AndrewPresident and CEOSSale−27.0K$20.02−$540.0K−4.7%552.5K after3 lots
Dec 5, 2023 (view filing)Nov 30-Dec 15 daysLateGraham G. WalmsleyDirectorPPurchase+100.0K$16.95+$1.69M+16.7%700.0K after2 lots
Nov 21, 2023 (view filing)Nov 174 daysYoung JonathanChief Operating OfficerSSale−30.0K$14.68−$440.4K−16.4%153.2K after
Oct 4, 2023 (view filing)Oct 22 daysCheng AndrewPresident and CEOSSale−25.0K$47.91−$1.20M−5.1%461.0K after5 lots
Oct 4, 2023 (view filing)Oct 22 daysYoung JonathanChief Operating OfficerSSale−490$51.10−$25.0K−0.3%183.2K after10b5-1
Sep 25, 2023 (view filing)Sep 1312 daysLateCheng AndrewPresident and CEOSSale−1.68K$50.34−$84.7K−0.4%461.0K after
Sep 25, 2023 (view filing)Sep 1312 daysLateWhite William RichardChief Financial OfficerSSale−632$50.34−$31.8K−3.3%18.5K after
Sep 25, 2023 (view filing)Sep 13-2112 daysLateYale CatrionaChief Development OfficerSSale−5.62K$48.32−$271.4K−10.9%46.0K after3 lots10b5-1
Sep 25, 2023 (view filing)Sep 1312 daysLateRolph TimothyChief Scientific OfficerSSale−531$50.34−$26.7K−0.4%150.7K after
Sep 25, 2023 (view filing)Sep 1312 daysLateYoung JonathanChief Operating OfficerSSale−562$50.34−$28.3K−0.3%183.2K after
Sep 18, 2023 (view filing)Sep 117 daysLateCheng AndrewPresident and CEOSSale−25.0K$49.77−$1.24M−5.1%462.7K after2 lots10b5-1
Aug 30, 2023 (view filing)Aug 282 daysYale CatrionaChief Development OfficerSSale−5.75K$49.99−$287.2K−11.0%46.6K after2 lots10b5-1
Aug 10, 2023 (view filing)Aug 82 daysGraham G. WalmsleyDirectorPPurchase+25.0K$42.06+$1.05M+4.3%600.0K after
Aug 3, 2023 (view filing)Aug 12 daysCheng AndrewPresident and CEOSSale−25.0K$43.15−$1.08M−5.3%447.7K after2 lots10b5-1
Aug 1, 2023 (view filing)Jul 28-Aug 14 daysGraham G. WalmsleyDirectorPPurchase+55.0K$42.95+$2.36M+10.6%575.0K after2 lots
Jul 6, 2023 (view filing)Jul 33 daysCheng AndrewPresident and CEOSSale−25.0K$44.88−$1.12M−5.3%447.7K after3 lots10b5-1
Jun 23, 2023 (view filing)Jun 21-232 daysYale CatrionaChief Development OfficerSSale−33.3K$51.74−$1.73M−41.7%46.6K after4 lots
Jun 22, 2023 (view filing)Jun 202 daysWhite William RichardChief Financial OfficerSSale−20.8K$55.00−$1.14M−52.1%19.1K after
Jun 21, 2023 (view filing)Jun 165 daysHeyman Tomas J.DirectorSSale−26.0K$54.67−$1.42M−100.0%0 after
Jun 21, 2023 (view filing)Jun 165 daysHenderson JaneDirectorSSale−40.0K$54.17−$2.17M−100.0%0 after2 lots
Jun 21, 2023 (view filing)Jun 165 daysRolph TimothyChief Scientific OfficerSSale−78.2K$54.79−$4.28M−34.1%151.2K after3 lots10b5-1
Jun 15, 2023 (view filing)Jun 132 daysWhite William RichardChief Financial OfficerSSale−606$55.16−$33.4K−2.6%22.4K after10b5-1
Jun 15, 2023 (view filing)Jun 132 daysCheng AndrewPresident & CEOSSale−1.61K$55.16−$89.0K−0.4%407.7K after10b5-1
Jun 15, 2023 (view filing)Jun 132 daysRolph TimothyChief Scientific OfficerSSale−509$55.16−$28.1K−0.3%189.4K after10b5-1
Jun 15, 2023 (view filing)Jun 132 daysYoung JonathanChief Operating OfficerSSale−538$55.16−$29.7K−0.3%183.7K after10b5-1